Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission

The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the treatment of a form of gastrointestinal disease. https://www.proactiveinvestors.com.au/companies/news/1018592/immuron-to-go-ahead-with-imm-529-cgmp-manufacturing-and-proceed-with-fda-pre-ind-submission-1018592.html

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.